When it matters the most.
The key to managing cancer is early detection. Bluestar Genomics makes this possible by finding signals of cancer in your blood early, when treatment is the most effective.
Bluestar Genomics’ proprietary epigenomic platform and cell-free DNA-based assays measure dynamic biological changes in cells to provide an early signal of a developing cancer.
Bluestar Genomics focuses on cancers with high mortality rates for which there are no or very limited screening options.
March 30, 2022
Bluestar Genomics to Participate in the Goldman Sachs 2022 Healthcare Disruption Conference
January 20, 2022
Bluestar Genomics Presents Positive Results of its Pancreatic Cancer Test Performance Evaluation at 2022 ASCO GI Cancers Symposium